5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Do O
not O
prescribe O
SINGULAIR O
to O
treat O
an O
acute O
asthma O
attack O
( O
5.1 O
) O
. O

* O
Advise O
patients O
to O
have O
appropriate O
rescue O
medication O
available O
( O
5.1 O
) O
. O

* O
Inhaled O
corticosteroid O
may O
be O
reduced O
gradually O
. O

Do O
not O
abruptly O
substitute O
SINGULAIR O
for O
inhaled O
or O
oral O
corticosteroids O
( O
5.2 O
) O
. O

* O
Patients O
with O
known O
aspirin O
sensitivity O
should O
continue O
to O
avoid O
aspirin O
or O
non-steroidal O
anti-inflammatory O
agents O
while O
taking O
SINGULAIR O
( O
5.3 O
) O
. O

* O
Neuropsychiatric O
events O
have O
been O
reported O
with O
SINGULAIR O
. O

Instruct O
patients O
to O
be O
alert O
for O
neuropsychiatric O
events O
. O

Evaluate O
the O
risks O
and O
benefits O
of O
continuing O
treatment O
with O
SINGULAIR O
if O
such O
events O
occur O
( O
5.4 O
and O
6.2 O
) O
. O

* O
Systemic O
eosinophilia O
, O
sometimes O
presenting O
with O
clinical O
features O
of O
vasculitis O
consistent O
with O
Churg-Strauss O
syndrome O
, O
has O
been O
reported O
. O

These O
events O
have O
been O
sometimes O
associated O
with O
the O
reduction O
of O
oral O
corticosteroid O
therapy O
( O
5.5 O
and O
6.2 O
) O
. O

* O
Inform O
patients O
with O
phenylketonuria O
that O
the O
4-mg O
and O
5-mg O
chewable O
tablets O
contain O
phenylalanine O
( O
5.6 O
) O
. O

5.1 O
Acute O
Asthma O
SINGULAIR O
is O
not O
indicated O
for O
use O
in O
the O
reversal O
of O
bronchospasm B-Not_AE_Candidate
in O
acute B-Not_AE_Candidate
asthma I-Not_AE_Candidate
attacks I-Not_AE_Candidate
, O
including O
status B-Not_AE_Candidate
asthmaticus I-Not_AE_Candidate
. O

Patients O
should O
be O
advised O
to O
have O
appropriate O
rescue O
medication O
available O
. O

Therapy O
with O
SINGULAIR O
can O
be O
continued O
during O
acute B-Not_AE_Candidate
exacerbations I-Not_AE_Candidate
of I-Not_AE_Candidate
asthma I-Not_AE_Candidate
. O

Patients O
who O
have O
exacerbations B-Not_AE_Candidate
of I-Not_AE_Candidate
asthma I-Not_AE_Candidate
after I-Not_AE_Candidate
exercise I-Not_AE_Candidate
should O
have O
available O
for O
rescue O
a O
short-acting O
inhaled O
beta-agonist O
. O

5.2 O
Concomitant O
Corticosteroid O
Use O
While O
the O
dose O
of O
inhaled O
corticosteroid O
may O
be O
reduced O
gradually O
under O
medical O
supervision O
, O
SINGULAIR O
should O
not O
be O
abruptly O
substituted O
for O
inhaled O
or O
oral O
corticosteroids O
. O

5.3 O
Aspirin O
Sensitivity O
Patients O
with O
known O
aspirin B-Not_AE_Candidate
sensitivity I-Not_AE_Candidate
should O
continue O
avoidance O
of O
aspirin O
or O
non-steroidal O
anti-inflammatory O
agents O
while O
taking O
SINGULAIR O
. O

Although O
SINGULAIR O
is O
effective O
in O
improving O
airway O
function O
in O
asthmatics B-Not_AE_Candidate
with O
documented O
aspirin B-Not_AE_Candidate
sensitivity I-Not_AE_Candidate
, O
it O
has O
not O
been O
shown O
to O
truncate O
bronchoconstrictor B-Not_AE_Candidate
response I-Not_AE_Candidate
to I-Not_AE_Candidate
aspirin I-Not_AE_Candidate
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
in O
aspirin B-Not_AE_Candidate
- I-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthmatic B-Not_AE_Candidate
patients O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.4 O
Neuropsychiatric O
Events O
Neuropsychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
in O
adult O
, O
adolescent O
, O
and O
pediatric O
patients O
taking O
SINGULAIR O
. O

Post-marketing O
reports O
with O
SINGULAIR O
use O
include O
agitation B-OSE_Labeled_AE
, O
aggressive B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
hostility B-OSE_Labeled_AE
, O
anxiousness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
dream B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
somnambulism B-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior I-OSE_Labeled_AE
( O
including O
suicide B-OSE_Labeled_AE
) O
, O
tic B-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
. O

The O
clinical O
details O
of O
some O
post-marketing O
reports O
involving O
SINGULAIR O
appear O
consistent O
with O
a O
drug-induced O
effect O
. O

Patients O
and O
prescribers O
should O
be O
alert O
for O
neuropsychiatric B-NonOSE_AE
events I-NonOSE_AE
. O

Patients O
should O
be O
instructed O
to O
notify O
their O
prescriber O
if O
these O
changes O
occur O
. O

Prescribers O
should O
carefully O
evaluate O
the O
risks O
and O
benefits O
of O
continuing O
treatment O
with O
SINGULAIR O
if O
such O
events O
occur O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Eosinophilic O
Conditions O
Patients O
with O
asthma B-Not_AE_Candidate
on O
therapy O
with O
SINGULAIR O
may O
present O
with O
systemic B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
, O
sometimes O
presenting O
with O
clinical O
features O
of O
vasculitis B-OSE_Labeled_AE
consistent O
with O
Churg B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Strauss I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
a O
condition O
which O
is O
often O
treated O
with O
systemic O
corticosteroid O
therapy O
. O

These O
events O
have O
been O
sometimes O
associated O
with O
the O
reduction O
of O
oral O
corticosteroid O
therapy O
. O

Physicians O
should O
be O
alert O
to O
eosinophilia B-NonOSE_AE
, O
vasculitic B-NonOSE_AE
rash I-NonOSE_AE
, O
worsening B-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
, O
cardiac B-NonOSE_AE
complications I-NonOSE_AE
, O
and/or O
neuropathy B-NonOSE_AE
presenting O
in O
their O
patients O
. O

A O
causal O
association O
between O
SINGULAIR O
and O
these O
underlying O
conditions O
has O
not O
been O
established O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.6 O
Phenylketonuria O
Phenylketonuric B-Not_AE_Candidate
patients O
should O
be O
informed O
that O
the O
4-mg O
and O
5-mg O
chewable O
tablets O
contain O
phenylalanine O
( O
a O
component O
of O
aspartame O
) O
, O
0.674 O
and O
0.842 O
mg O
per O
4-mg O
and O
5-mg O
chewable O
tablet O
, O
respectively O
. O

